

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




D-serine transport antagonists for treatment of schizophrenia

Inventor: Daniel C. Javitt



Positive and Negative Symptom Scale (PANSS) – 5 factor model

Positive Delusions Unusual thought content Grandiosity Suspiciousness/persecution	Negative Emotional withdrawal Passive/apathetic withdrawal Lack of spontaneity Poor rapport Blunted affect Active social avoidance	
Cognitive Conceptual disorganization Disorientation Difficulty in abstract thinking Mannerisms and posturing Poor attention	Excitement Excitement Poor impulse control Hostility Tension	Depression Anxiety Guilt feelings Depression Somatic concern Preoccupation



D-Serine 0.03 g/kg/day (2.1 g/day) - Taiwan


Positive

Negative

Cognitive

Neuropsych

	Placebo	D-serine	(F, p)
WCST category			
Boulier	2.3 (4.2)	2.3 (3.4)	
G1 index	4.9 (1.2)	3.7 (4.0)	(4.1, .02)
WCST perseverative error			
Boulier	3.6 (1.6)	3.2 (1.6)	
G1 index	4.9 (3.0)	3.8 (3.2)	ns
CTC			
Boulier	4.3 (2.6)	4.8 (2.7)	
G1 index	4.8 (1.1)	2.8 (1.1)	(16.8, <.001)





Analogy

Administering Glycine, D-serine is analogous to turning on faucet



Administering D-serine transport inhibitors is analogous to blocking the drain



Application demonstrates:

- Novel, D-serine transport system
- Novel compounds that block the novel system
 - D-serine dodecylamide
 - D-alanine dodecylamide
- Animal behavioral effects related to blockade
- Changes in in vivo NMDA binding related to novel compounds

US Appl 10/066,657

Issue 1: Were compositions known prior to submission?

Answer: No

Glycyl dodecylamide was previously known

D-serine dodecylamide, D-alanine dodecylamide are novel compounds not previously known

Issue 2: What is undue experimentation?

Answer 1: Development of new drug for clinical treatment costs over \$100M and takes over 5 yrs. Development of listed derivatives cost <\$100K and took <6 mo. Objective criteria for undue experimentation need to be specified.

Issue 2: What is undue experimentation?

Answer 2: Only 2 compounds are needed to claim the genus. In case of this application, glycyl dodecylamide, D-serine dodecylamide and D-alanine dodecylamide establish the genus



Control number 09/956,034

Issue 1: Do D-serine and D-serine transport inhibitors have a "common" mechanism of action?

Answer: No

1. D-serine does not inhibit D-serine transport

Proof: In example 1, D-[3H]serine is shown to be transported

2. GDA, DSerDA & DAAlaDA do not bind to NMDA receptor

Proof: example 2, the NMDA glycine-site antagonist HA-966 was used to exclude the possibility that the prototype d-serine transport inhibitors described in the present application worked by binding to the NMDA glycine site (US2002/018 3390 A1, p. 2, last 4 lines - p. 3, 1st line)

Issue 2: Is D-serine the "active ingredient" of the compounds described in the specification?

Answer: No

None of the compounds described in the application contains the molecular entity D-serine. D-serine dodecylamide is a compound in which 12 carbons are added to a D-serine backbone. This is a different molecular entity. Two of the compounds, glycyldodecylamide and D-alanine dodecylamide, do not even have D-serine in their chemical composition.

Issue 3: "patient, condition to be treated and effect are all the same"

This is not a reasonable standard. This would imply that no new treatment for negative symptoms of schizophrenia could ever be patented since patient (schizophrenic), condition (negative symptoms) and effect (improvement) are all the same.

Molecular mechanism of action of D-serine and D-serine transport inhibitors are not the same

Issue 4: Compounds set forth in the appendix were not in the original application

Compounds demonstrate that one skilled in the art, using information set forth in the application could practice the invention without undue experimentation

Compounds synthesized for <\$100K using commercial synthesis laboratory (Albany Molecular) in under 6 mo

Undue experimentation not required